You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Duvelisib

Showing 1 - 25 of 48
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

(CHANT)Real World Study of Duvelisib in Treatment of

Not yet recruiting
  • Follicular Lymphoma
  • +5 more
  • Duvelisib
  • (no location specified)
Jun 20, 2023

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Wuhan (Duvelisib, Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Duvelisib, Chidamide
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Jul 27, 2023

Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloma Trial in Tampa (CC-486, Duvelisib)

Recruiting
  • Non Hodgkin Lymphoma
  • +3 more
  • Tampa, Florida
    Moffitt Cancer Center
Jan 18, 2023

COVID-19 Trial in Saint Louis (Duvelisib, Peripheral blood draw, Placebo)

Completed
  • COVID-19
  • Duvelisib
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Aug 9, 2022

Squamous Cell Carcinoma of the Head and Neck (SCCHN), Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Head

Recruiting
  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • +4 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 19, 2023

T-Cell Lymphoma Trial in Saint Louis (Duvelisib, Peripheral blood draw)

Recruiting
  • T-Cell Lymphoma
  • Duvelisib
  • Peripheral blood draw
  • Saint Louis, Missouri
    Washington University School of Medicine
Jul 18, 2022

Advanced Solid Tumors Trial (Duvelisib, SG001)

Not yet recruiting
  • Advanced Solid Tumors
  • (no location specified)
Aug 18, 2022

Non-hodgkin Lymphoma, Acute Lymphocytic Leukemia Trial in Saint Louis (Duvelisib)

Recruiting
  • Non-hodgkin Lymphoma
  • Acute Lymphocytic Leukemia
  • Duvelisib
  • Saint Louis, Missouri
    Washington University School of Medicine
Jun 30, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia Trial in

Active, not recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +3 more
  • Duvelisib
  • Duarte, California
  • +2 more
Oct 7, 2022

Chronic Lymphocytic Leukemia, Richter Syndrome Trial in United States (Duvelisib, Venetoclax)

Recruiting
  • Chronic Lymphocytic Leukemia
  • Richter Syndrome
  • Miami, Florida
  • +6 more
Jan 6, 2023

COVID-19 Trial in Atlanta (Duvelisib, Placebo)

Completed
  • COVID-19
  • Duvelisib
  • Placebo
  • Atlanta, Georgia
  • +2 more
Jun 10, 2022

Unresectable Melanoma Trial in Pittsburgh (Nivolumab, Duvelisib)

Recruiting
  • Unresectable Melanoma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Apr 19, 2022

Adult T-cell Leukemia/Lymphoma, Extranodal NK-/T-cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma Trial run by

Not yet recruiting
  • Adult T-cell Leukemia/Lymphoma
  • +4 more
  • CC-486 (5-azacitidine)
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Small Lymphocytic Leukemia (SLL), Chronic Lymphocytic Leukemia (CLL) Trial run by the NHLBI (Duvelisib, Ibrutinib)

Terminated
Has Results
  • Small Lymphocytic Leukemia (SLL)
  • Chronic Lymphocytic Leukemia (CLL)
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 15, 2022

Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma Trial (Acalabrutinib,

Withdrawn
  • Recurrent Follicular Lymphoma
  • +8 more
  • (no location specified)
Jun 2, 2022

Lymphoma, Relapsed/Refractory T-cell Lymphomas Trial in United States (Romidepsin, Bortezomib, duvelisib)

Active, not recruiting
  • Lymphoma
  • Relapsed/Refractory T-cell Lymphomas
  • Stanford, California
  • +10 more
Feb 2, 2023

T-cell Lymphomas, NK-Cell Lymphomas Trial in United States (Ruxolitinib, Duvelisib)

Recruiting
  • T-cell Lymphomas
  • NK-Cell Lymphomas
  • Miami, Florida
  • +8 more
Aug 1, 2022

Peripheral T-cell Lymphoma Trial in Worldwide (Duvelisib)

Active, not recruiting
  • Peripheral T-cell Lymphoma
  • Duvelisib
  • Duarte, California
  • +27 more
May 3, 2022

Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV

Recruiting
  • Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8
  • +2 more
  • Duvelisib
  • +2 more
  • Phoenix, Arizona
  • +11 more
Aug 6, 2022

Peripheral T Cell Lymphoma Trial (CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • (no location specified)
Dec 29, 2022

Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma Trial in United States

Recruiting
  • Angioimmunoblastic T-cell Lymphoma
  • +6 more
  • Los Angeles, California
  • +20 more
Aug 2, 2022

Healthy Trial in Lenexa (IPI-145 (duvelisib), IPI-145)

Completed
  • Healthy
  • Lenexa, Kansas
    (unnamed)
Mar 15, 2021

Hematologic Malignancies Trial in United States (IPI-145 (duvelisib))

Terminated
  • Hematologic Malignancies
  • IPI-145 (duvelisib)
  • New York, New York
  • +3 more
Mar 15, 2021

Lymphocytic Leukemia, Chronic, Lymphoma, Small Lymphocytic Trial in Canada, United States (IPI-145 (duvelisib), Obinutuzumab)

Terminated
  • Lymphocytic Leukemia, Chronic
  • Lymphoma, Small Lymphocytic
  • La Jolla, California
  • +6 more
Mar 15, 2021

Hematologic Malignancy Trial in Italy, United States (Duvelisib)

Completed
  • Hematologic Malignancy
  • Duvelisib
  • Denver, Colorado
  • +4 more
Mar 15, 2021